Pain is a frequent problem for people with recessive dystrophic epidermolysis bullosa (RDEB), and available medications are often not…
Articles by Marisa Wexler, MS
Treatment with SNT-6935, an experimental compound that acts to reduce the activity of an enzyme that breaks down proteins, reduced…
Scientists have devised a new, more efficient method to create gene-edited stem cell therapies for dystrophic epidermolysis bullosa (DEB).
Both bone marrow transplant and treatment with stem cells derived from bone marrow may help ease symptoms in some people…
Dupilumab, an injection therapy approved for certain inflammatory disorders, may be an effective option to help ease itch and reduce…
An inflammatory signaling molecule called interleukin-6 (IL-6) is produced at high levels in skin wounds of people with recessive…
Abeona Therapeutics said its gene-corrected cell therapy, called pz-cel (prademagene zamikeracel), for recessive dystrophic epidermolysis bullosa (RDEB), is…
Almirall has licensed rights to develop and commercialize ZKN-013, an experimental oral treatment for recessive dystrophic epidermolysis…
The gene therapy beremagene geperpavec (B-VEC), applied directly as eye drops, improved the vision in a boy with eye scarring…
The U.S. Food and Drug Administration (FDA)’s review of pz-cel (prademagene zamikeracel), a gene-corrected cell therapy for recessive dystrophic…
Treatment with baricitinib or upadacitinib, two approved medications for rheumatoid arthritis, may be effective for relieving itching in some people…
The U.S. Food and Drug Administration (FDA) has approved Filsuvez (birch triterpenes) to treat skin wounds in patients with…